Key Points
- Insider selling: Omada Health CAO Craig Gracey sold 644 shares for approximately $13,994, reducing his direct stake by 4.28% to 14,412 shares. The transaction follows several earlier sales since late June.
- Stock performance and results: OMDA shares opened at $19.66 and were reported down 8.6%, despite the company exceeding quarterly expectations with $0.08 in EPS versus a $0.02 loss estimate and $87.83 million in revenue.
- Analyst outlook remains positive: Analysts maintain a “Moderate Buy” consensus, with an average price target of $26.67 versus the reported share price, while several firms recently raised targets or reaffirmed buy-equivalent ratings.
Omada Health, Inc. (NASDAQ:OMDA - Get Free Report) CAO Craig Gracey sold 644 shares of the company's stock in a transaction dated Wednesday, September 9th. The stock was sold at an average price of $21.73, for a total transaction of $13,994.12. Following the completion of the sale, the chief accounting officer directly owned 14,412 shares of the company's stock, valued at $313,172.76. The trade was a 4.28% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link.
Craig Gracey also recently made the following trade(s):
- On Monday, August 10th, Craig Gracey sold 1,042 shares of Omada Health stock. The shares were sold at an average price of $25.00, for a total transaction of $26,050.00.
- On Wednesday, July 1st, Craig Gracey sold 637 shares of Omada Health stock. The stock was sold at an average price of $23.00, for a total value of $14,651.00.
- On Tuesday, June 30th, Craig Gracey sold 405 shares of Omada Health stock. The shares were sold at an average price of $22.00, for a total value of $8,910.00.
- On Monday, June 29th, Craig Gracey sold 2,083 shares of Omada Health stock. The shares were sold at an average price of $21.00, for a total value of $43,743.00.
- On Friday, June 26th, Craig Gracey sold 2,084 shares of Omada Health stock. The shares were sold at an average price of $20.00, for a total value of $41,680.00.
- On Wednesday, June 24th, Craig Gracey sold 2,083 shares of Omada Health stock. The stock was sold at an average price of $19.01, for a total value of $39,597.83.
- On Monday, June 22nd, Craig Gracey sold 2,083 shares of Omada Health stock. The shares were sold at an average price of $18.00, for a total value of $37,494.00.
Omada Health Stock Down 8.6%
Shares of OMDA stock opened at $19.66 on Friday. The stock has a 50-day simple moving average of $22.63 and a 200 day simple moving average of $17.92. The stock has a market capitalization of $1.20 billion, a P/E ratio of 393.20 and a beta of 1.86. Omada Health, Inc. has a fifty-two week low of $10.28 and a fifty-two week high of $26.92.
Omada Health (NASDAQ:OMDA - Get Free Report) last issued its quarterly earnings results on Thursday, August 6th. The company reported $0.08 EPS for the quarter, topping the consensus estimate of ($0.02) by $0.10. Omada Health had a net margin of 1.39% and a return on equity of 2.60%. The firm had revenue of $87.83 million for the quarter, compared to analysts' expectations of $80.93 million. On average, sell-side analysts anticipate that Omada Health, Inc. will post 0.09 earnings per share for the current year.
Institutional Trading of Omada Health
A number of hedge funds have recently bought and sold shares of OMDA. Quarry LP acquired a new position in shares of Omada Health in the fourth quarter worth about $29,000. Raymond James Financial Inc. acquired a new stake in shares of Omada Health during the second quarter valued at approximately $32,000. Integrated Wealth Concepts LLC purchased a new stake in shares of Omada Health in the 2nd quarter valued at approximately $53,000. Versant Capital Management Inc lifted its position in shares of Omada Health by 319.3% in the 2nd quarter. Versant Capital Management Inc now owns 2,998 shares of the company's stock valued at $66,000 after acquiring an additional 2,283 shares in the last quarter. Finally, New York State Common Retirement Fund acquired a new position in Omada Health in the 4th quarter worth approximately $73,000.
Key Omada Health News
Here are the key news stories impacting Omada Health this week:
- Positive Sentiment: Analyst support remains strong: BTIG Research reaffirmed its “buy” rating and set a $35 price target, while Needham & Company also maintained a “buy” rating with a $28 target. These targets imply significant potential upside and reinforce confidence in Omada’s growth outlook.
- Positive Sentiment: Investor Day could provide new growth targets: Omada held its inaugural Investor Day and planned to present updated long-term financial targets. More ambitious revenue, profitability, or membership goals could improve investor confidence if management’s outlook exceeds current expectations. Omada Health to Present Updated Long-Term Financial Targets at Inaugural Investor Day
- Neutral Sentiment: Investor Day transcript available: The transcript may offer additional detail on Omada’s strategy and financial targets, but the supplied report does not identify specific changes that would immediately alter earnings expectations. Omada Health Analyst/Investor Day Transcript
- Negative Sentiment: Chief accounting officer sold shares: CAO Craig Gracey sold 644 shares for approximately $14,000, reducing his direct ownership by 4.28%. The relatively small transaction is not necessarily a sign of deteriorating fundamentals, but insider selling can create short-term negative sentiment. SEC Insider Transaction Filing
Wall Street Analyst Weigh In
A number of analysts recently weighed in on OMDA shares. BTIG Research restated a "buy" rating and set a $35.00 target price on shares of Omada Health in a report on Friday. Barclays upped their price target on Omada Health from $25.00 to $27.00 and gave the company an "overweight" rating in a report on Friday. Citizens Jmp increased their price objective on Omada Health from $27.00 to $32.00 and gave the company a "market outperform" rating in a research report on Friday, August 14th. Wall Street Zen raised Omada Health from a "hold" rating to a "buy" rating in a research note on Saturday, August 8th. Finally, Needham & Company LLC restated a "buy" rating and issued a $28.00 target price on shares of Omada Health in a report on Friday. Eleven research analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat, the company has an average rating of "Moderate Buy" and an average target price of $26.67.
Read Our Latest Stock Analysis on Omada Health
Omada Health Company Profile
(
Get Free Report)
Omada Health is a digital health company that specializes in the prevention and management of chronic conditions through personalized, technology-driven programs. The company's platform combines data analytics, behavioral science and human coaching to support individuals at risk for or living with conditions such as prediabetes, type 2 diabetes, hypertension and musculoskeletal disorders. Participants access the program via a mobile app or web portal, where they receive tailored curriculum, feedback on health metrics and ongoing virtual coaching.
In addition to its core disease-management offerings, Omada Health has expanded its services to include mental health support and digital therapeutics for weight management.
Featured Stories
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
